Acquisitions Purchase Price (Details) - USD ($) $ / shares in Units, $ in Millions				2 Months Ended	9 Months Ended
	Sep. 30, 2021	Feb. 25, 2021	Jan. 15, 2021	Dec. 31, 2021	Oct. 02, 2021	Sep. 26, 2020	Apr. 15, 2021
Business Acquisition [Line Items]
Net Cash Consideration					$ 1,519	$ 3
Purchase Price
Fair value of contingent consideration					$ 179
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					9 years
Customer Relationships [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					14 years
Product Technology [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					7 years
Tradenames [Member]
Net Assets Acquired [Abstract]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life (in years)					3 years
PPD, Inc [Member]
Business Acquisition [Line Items]
Percent of PPD's outstanding shares that have approved the proposed acquisition							60.00%
European Viral Vector Manufacturing Business
Business Acquisition [Line Items]
Net Cash Consideration			$ 834
Purchase Price
Cash paid			853
Cash acquired			(19)
Total Purchase Price			834
Net Assets Acquired [Abstract]
Current assets			39
Property, plant and equipment			59
Goodwill			603
Other assets			4
Contract Liabilities			(59)
Deferred tax liabilities			(80)
Finance lease liabilities			(24)
Other liabilities assumed			(35)
Net Assets Acquired			834
European Viral Vector Manufacturing Business | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			302
European Viral Vector Manufacturing Business | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets			$ 25
Mesa Biotech
Business Acquisition [Line Items]
Net Cash Consideration		$ 409
Purchase Price
Cash paid		423
Fair value of contingent consideration		65
Cash acquired		(14)
Total Purchase Price		474
Net Assets Acquired [Abstract]
Current assets		54
Property, plant and equipment		2
Goodwill		239
Other assets		4
Deferred tax liabilities		(72)
Finance lease liabilities		(1)
Other liabilities assumed		(33)
Net Assets Acquired		474
Mesa Biotech | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		279
Mesa Biotech | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets		$ 2
Lengnau biologics manufacturing facility
Business Acquisition [Line Items]
Lessee, Lease Liability Payments Due	$ 555
Purchase Price
Fair value of contingent consideration	1
Purchase price payable	17
Total Purchase Price	18
Net Assets Acquired [Abstract]
Property, plant and equipment	92
Goodwill	18
Other assets	361
Finance lease liabilities	(82)
Other liabilities assumed	(371)
Net Assets Acquired	$ 18
Other [Member]
Purchase Price
Cash paid					$ 287
Fair value of contingent consideration					113
Cash acquired					(11)
Total Purchase Price					389
Net Assets Acquired [Abstract]
Current assets					10
Property, plant and equipment					3
Goodwill					190
Contract Liabilities					(1)
Deferred tax liabilities					(28)
Other liabilities assumed					(10)
Net Assets Acquired					389
Other [Member] | Customer Relationships [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					2
Other [Member] | Product Technology [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					220
Other [Member] | Tradenames [Member]
Net Assets Acquired [Abstract]
Definite-lived intangible assets					$ 3
Forecast [Member] | PPD, Inc [Member]
Business Acquisition [Line Items]
Business Acquisition, Share Price				$ 47.50
Purchase Price
Cash paid				$ 17,400
Net Assets Acquired [Abstract]
Debt assumed				$ (3,500)